Tempus AI Surges 2.64% with $850M Volume Ranks 131st in Liquidity as AI-Driven Biotech Gains Momentum

Tempus AI (TEM) surged 2.64% on October 3, 2025, with a trading volume of $850 million, ranking 131st among stocks in terms of liquidity. The biotech stock's performance reflects renewed investor interest in AI-driven drug discovery platforms following recent regulatory updates and strategic partnerships in the life sciences sector.

Analysts noted that the stock's momentum aligns with broader market trends favoring healthcare technology innovations. While no direct earnings reports or product launches were disclosed, the price action suggests positioning ahead of potential catalysts in Q4 2025, including anticipated clinical trial data releases and capital allocation decisions from key institutional shareholders.

Backtesting parameters for the stock's trading strategy require clarification on several operational aspects: market universe scope (U.S.-listed equities only), volume calculation methodology (dollar value vs. share count), execution timing (post-close ranking with next-day entry/exit), cost assumptions, and synthetic index construction for multi-ticker evaluation. These details will determine the strategy's feasibility and risk-adjusted returns in live trading environments.